88%Confidence
0Views
FDASource
2026-03-31Date
Summary
Harbin Jixianglong's Semaglutide recall due to incomplete validation processes highlights significant regulatory risks in the compounding pharmacy supply chain, especially for high-demand GLP-1 analogs. This creates supply constraints for compounding pharmacies and increases scrutiny on imported active pharmaceutical ingredients for weight loss medications.
Actionable: Immediately verify the source of Semaglutide API in your supply chain and consider alternative approved suppliers with complete validation documentation.
AI Confidence: 88%
Data Points
firmHarbin Jixianglong Biotech Co., Ltd.
classificationClass II
statusOngoing
distributionNationwide within the United States
productSemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-1
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now